Qiagen aspires to leadership in personalised medicine
This article was originally published in Scrip
Executive Summary
For anyone following the fastest-growing companies in the companion diagnostics sector, last month’s acquisition of DxS by Qiagen for up to $130m was no surprise. Qiagen has had its eye on personalised healthcare for quite a while now, and DxS is a very promising addition to the Venlo-based company.